No Data
No Data
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
Express News | HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $34 Price Target
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave
Cullinan Oncology (CGEM) said Thursday that its Chief Financial Officer Jeffrey Trigilio is leaving the company, effective March 29. Trigilio agreed to support Cullinan through the transition period a
Express News | Cullinan Oncology Q4 EPS $(0.54) Beats $(0.96) Estimate; Cash And Investments Of $468.3M As Of December 31, 2023 Continues To Provide Runway Into The Second Half Of 2026
-Cullinan Oncology 4Q Loss/Shr $0.54 >CGEM
-Cullinan Oncology 4Q Loss/Shr $0.54 >CGEM
Press Release: Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619
No Data
SpyderCall : Everything is getting clobbered
Hani Ayyash SpyderCall: Exactly what I was thinking lmao
obliging Wolf_5187 : Automotive companies in the dumps too.